Oncotelic Therapeutics (Oncotelic Therapeutics) GF Score : 0/100 (As of May. 06, 2024)

View and export this data going back to 1993. Start your Free Trial

What is Oncotelic Therapeutics GF Score?

Oncotelic Therapeutics has the GF Score of 0, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 0/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Oncotelic Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Oncotelic Therapeutics (OTCPK:OTLC) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Oncotelic Therapeutics GF Score Related Terms

Thank you for viewing the detailed overview of Oncotelic Therapeutics's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncotelic Therapeutics (Oncotelic Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncotelic Therapeutics Inc (OTCPK:OTLC) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

29397 Agoura Road, Suite 107, Agoura Hills, CA, USA, 91301

Website

https://www.oncotelic.com

Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.

Executives

Vuong Trieu	officer: CHIEF EXECUTIVE OFFICER	4003 JIM BOWIE ROAD, AGOURA HILLS CA 91301
Saran Saund	officer: CHIEF BUSINESS OFFICER	C/O MATEON THERAPEUTICS INC., 29397 AGOURA RD SUTIE 107, AGOURA HILLS CA 91301
Amit B. Shah	officer: CHIEF FINANCIAL OFFICER	10 AGUILA, ALISO VIEJO CA 92656
Chulho Park	officer: CHIEF TECHNOLOGY OFFICER	701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Maida Anthony E Iii	director	157 TECHNOLOGY DR, IRVINE CA 92618
Steven W King	director
David Diamond	director	29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301
Fatih Uckun	10 percent owner, officer: Chief Medical Officer	701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Chao Hsiao	10 percent owner	701 GATEWAY BOULEVARD, SUITE 201, SOUTH SAN FRANCISCO CA 94080
Larn Hwang	10 percent owner	C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Donald Rogers Reynolds	director	C/O WYRICK ROBBINS YATES & PONTON LLP, 4101 LAKE BOONE TRAIL, SUITE 300, RALEIGH NC 27607
Sandage Bobby W Phd	director	C/O 99 HAYDEN AVE, 1 LEDGEMONT CENTER, LEXINGTON MA 02173
Simon Pedder	director	1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Matthew M Loar	officer: Chief Financial Officer	505 PENOBSCOT DR, REDWOOD CITY CA 94063
Pamela Ha	officer: Controller	701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080